Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Auckland cancer drug discovery gets funding boost

Auckland cancer drug discovery gets funding boost


Significant research at the University of Auckland into the discovery and development of new drugs to improve patient outcomes in radiation therapy was one of the high profile research programmes funded in the latest round of Health Research Council grants.

Professor Bill Wilson and his multidisciplinary team from the University-based Auckland Cancer Society Research Centre (ACSRC) were granted nearly $5 million over the next five years to develop new drugs for this neglected setting, and for identifying genetic biomarkers that will match these drugs to patients who will most benefit.

“This grant provides critical support for the overall effort in targeting hypoxia in tumours at the University of Auckland,” says Professor Wilson. Another ACSRC member Associate Professor Adam Patterson also gained funding for two smaller projects in a related area of this research.

The new research programme entitled ‘Biomarker-guided drug targeting of the tumour microenvironment in radiotherapy’ is primarily a drug discovery programme.

“We are looking at taking forward a class of drugs that we understand in detail through Senior Research Fellow Dr Moana Tercel’s medicinal chemistry work, and we expect to be able to identify a clinical candidate in this series in the next year,” says Professor Wilson.

“The programme also involves two early stage drug discovery projects which Associate Professor Michael Hay leads. There is exciting potential here that builds on the understanding that we have developed over some years about targeting hypoxia,” he says.

“The other half of the programme seeks to understand how to identify the patients who will benefit from these drugs. We will be investigating biomarkers that predict which tumours will respond,” says Professor Wilson. “This is a neglected field with great promise.”

“Drug development in the 21st century must move away from huge clinical trials with unselected patients towards targeting drugs to tumours based on their molecular profile.”
The team will focus on head and neck cancers because there is an important need for new drugs in the treatment of these cancers.

“That is the clinical setting where we have the strongest evidence that tumour hypoxia is a major problem,” says Professor Wilson. “Hypoxic tumour cells are not eliminated by conventional radio-therapy, so this is an ideal setting to develop these agents.”

“The key is using our existing knowledge and matching the patient tumour profile with the new drug,” he says. “We know that this is necessary to advance drugs through the clinical development phase.”

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Genetics: New Heat Tolerant Cow Developed

Hamilton, New Zealand-based Dairy Solutionz Ltd has led an expert genetics team to develop a new dairy cow breed conditioned to thrive in lower elevation tropical climates and achieve high milk production under heat stress. More>>

Fractals: Thousands More Business Cards Needed To Build Giant Sponge

New Zealand is taking part in a global event this weekend to build a Menger Sponge using 15 million business cards but local organisers say they are thousands of business cards short. More>>

Scoop Business: NZ Net Migration Rises To Annual Record In September

New Zealand’s annual net migration rose to a record in September, beating government forecasts, as the inflow was spurred by student arrivals from India and Kiwis returning home from Australia. More>>

ALSO:

Scoop Business: Fletcher To Close Its Christchurch Insulation Plant, Cut 29 Jobs

Fletcher Building, New Zealand’s largest listed company, will close its Christchurch insulation factory, as it consolidates its Tasman Insulations operations in a “highly competitive market”. More>>

ALSO:

Scoop Business: Novartis Adds Nine New Treatments Under Pharmac Deal

Novartis New Zealand, the local unit of the global pharmaceuticals firm, has added nine new treatments in a far-ranging agreement with government drug buying agency, Pharmac. More>>

ALSO:

Crown Accounts: English Wary On Tax Take, Could Threaten Surplus

Finance Minister Bill English is warning the tax take may come in below forecast in the current financial year, as figures released today confirm it was short by nearly $1 billion in the year to June 30 and English warned of the potential impact of slumping receipts from agricultural exports. More>>

ALSO:

Auckland Outage: Power Mostly Restored Overnight

Vector wishes to advise that all but 324 customers have been restored overnight. These customers are spread throughout the network in small pockets. The main St Johns feeder was restored around midnight allowing most of the customers in all affected areas to have power this morning. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand

Mosh Social Media
 
More RSS  RSS
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news